

TABLE 1: CLINICO-PATHOLOGICAL CHARACTERISTICS OF MALIGNANT GCTs (n-254)							
STUDY CHARACTERISTIC	TESTICULAR (n-48)		OVARIAN (n-114)		EXTRAGONADAL (n-92)		OVERALL
	n	%	n	%	n	%	n
<b>GENDER</b>							
Female	-	-	114	70.20	48	29.80	162
Male	48	52.20	-	-	44	47.80	92
<b>AGE DISTRIBUTION</b>							
< 3 years	41	37.30	1	0.90	68	61.80	110
3-11 years	4	6.90	42	70.70	13	22.40	59
> 11 years	3	3.50	71	83.50	11	12.90	85
<b>STAGE</b>							
Stage I	16	69.60	7	30.40	-	-	23
Stage II	14	46.70	14	46.70	2	6.60	30
Stage III	6	4.80	74	58.70	46	36.50	126
Stage IV	12	16.20	19	24.30	44	59.50	75
<b>HISTOLOGY</b>							
Yolk Sac/Endodermal Sinus tumor	38	35.20	25	22.20	46	42.60	109
Dysgerminoma/Seminoma	1	2.40	37	90.20	3	7.30	41
Mixed GCT	6	12.80	30	63.80	11	23.40	47
Embryonal Carcinoma	-	-	5	83.30	1	16.70	6
Choriocarcinoma	-	-	3	75.00	1	25.00	4
Teratoma (post chemotherapy)	3	6.80	13	29.50	28	63.70	44
HPR not available	-	-	1	33.30	2	66.70	3
<b>TMH RISK STRATIFICATION</b>							
Low Risk	16	69.60	7	30.40	-	-	23
Intermediate Risk	32	26.20	88	72.20	2	1.60	122
High Risk	-	-	19	16.70	90	83.30	109
<b>CHEMOTHERAPY REGIMEN (n-231)</b>							
Cisplatin	26	14.40	95	52.20	60	33.30	181
Carboplatin	2	7.40	7	25.90	18	66.70	27
Cisplatin + Carboplatin	4	17.40	5	21.70	14	60.90	23
<b>MaGIC RISK (n-192)</b>							
Standard Risk 1	29	21.30	29	21.30	78	57.40	136
Standard Risk 2	-	-	31	100	-	-	31
Poor Risk	2	8.0	14	56.00	9	36.00	25